Loading...
Plasma exchange and intravenous immunoglobulin have been considered effective treatments for Guillain-Barré syndrome (GBS) since the 1980s and 1990s, respectively. However even with the best available therapy, the mortality rate is still approximately 5%, and 20% of patients cannot walk unaided 6 months after onset. Some patients with GBS develop severe weakness and a long disease course, which require more-effective novel treatments to improve survival and functional recovery.
This study was a 24-week, multicenter, double-blind, placebo-controlled, randomized, manufacturer-funded phase II trial done in 13 hospitals in Japan. Eligible patients with GBS were 18 years or older and could not walk independently. The 34 patients were randomized t…